Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study

Oliviero Rossi, Angelo Piccirillo, Enrico Iemoli, Annalisa Patrizi, Luca Stingeni, Stefano Calvieri, Massimo Gola, Paolo Dapavo, Antonio Cristaudo, Leonardo Zichichi, Laura Losappio, Fabiana Saccheri, Elide Anna Pastorello

Research output: Contribution to journalArticlepeer-review


Introduction: In Italy, the real-world evidence on the extent of adherence to guidelines and the benefits of recommended therapeutic medications and their impact on the quality of life (QoL) of H1-antihistamines (H1-AH) refractory chronic urticaria (CU) patients is limited. Methods: AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) was a global prospective, non-interventional study of CU in real-world setting which included patients aged ≥18 years with a medically confirmed diagnosed of CU present for more than 2 months. In this study, the disease characteristics, pharmacological treatments and patient-reported outcomes (PROs) are reported. Results: In total, 159 patients from 24 study centres in Italy completed the study. At baseline, 221 (89.5%) and 8 (3.2%) patients had chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), respectively, while 18 (7.3%) patients had concomitant CSU and CIndU. For CSU patients, mean dermatology life quality index and CU quality of life questionnaire scores reduced to 3.0 ± 4.9 and 14.6 ± 18.6 at Month 24 from baseline scores of 7.5 ± 6.6 and 33.2 ± 19.5, respectively, indicating an improvement in QoL. This was reflected in their work-life as work productivity impairment reduced considerably after 2 years. Only 71.9% CSU patients had a prior treatment, while during the study, 96.8% of the patients were treated with a medication. At baseline, only 52.9% CSU patients reported nonsedating H1-antihistamines as first-line of treatment in prior medication, this increased to 89.6% during current medication. Conclusion: This study shows that CSU has a considerable socio-economic burden and an improvement in QoL can be achieved in CSU patients if an appropriate therapeutic path is followed.

Original languageEnglish
Article number100470
JournalWorld Allergy Organization Journal
Issue number12
Publication statusPublished - Dec 2020


  • AWARE study
  • Chronic spontaneous urticaria
  • Italy
  • Resource utilisation
  • Socio-economic burden

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study'. Together they form a unique fingerprint.

Cite this